Practical radiation oncology · 2020
Consensus Statement on Proton Therapy in Mesothelioma.
СтатьяОбзорConsensus StatementНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeng Jing, Badiyan Shahed N, Garces Yolanda I, Wong Tony, Zhang Xiaodong, Simone Charles B, Chang Joe Y, Knopf Antje C, Mori Shinichiro, Iwata Hiromitsu, Meijers Arturs, Li Heng, Bues Martin, Liu Wei, Schild Steven E, Rengan Ramesh, International Particle Therapy Cooperative Group Thoracic Subcommittee
Аннотация
PURPOSE: Radiation therapy for mesothelioma remains challenging, as normal tissue toxicity limits the amount of radiation that can be safely delivered to the pleural surfaces, especially radiation dose to the contralateral lung. The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the postpneumonectomy setting and the lung-intact setting. Compared with photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach. However, the tissue heterogeneity in the thorax, organ motion, and potential for changing anatomy during the treatment course all present challenges to optimal irradiation with protons.
METHODS: The clinical data underlying proton therapy in mesothelioma are reviewed here, including indications, advantages, and limitations.
RESULTS: The Particle Therapy Cooperative Group Thoracic Subcommittee task group provides specific guidelines for the use of proton therapy for mesothelioma.
CONCLUSIONS: This consensus report can be used to guide clinical practice, insurance approval, and future research.
METHODS: The clinical data underlying proton therapy in mesothelioma are reviewed here, including indications, advantages, and limitations.
RESULTS: The Particle Therapy Cooperative Group Thoracic Subcommittee task group provides specific guidelines for the use of proton therapy for mesothelioma.
CONCLUSIONS: This consensus report can be used to guide clinical practice, insurance approval, and future research.